These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 26122229)
1. EFFECT OF PREGNANE XENOBIOTIC RECEPTOR ACTIVATION ON INFLAMMATORY BOWEL DISEASE TREATED WITH RIFAXIMIN. Wan YC; Li T; Han YD; Zhang HY; Lin H; Zhang B J Biol Regul Homeost Agents; 2015; 29(2):401-10. PubMed ID: 26122229 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. Cheng J; Shah YM; Ma X; Pang X; Tanaka T; Kodama T; Krausz KW; Gonzalez FJ J Pharmacol Exp Ther; 2010 Oct; 335(1):32-41. PubMed ID: 20627999 [TBL] [Abstract][Full Text] [Related]
3. Rifaximin is a gut-specific human pregnane X receptor activator. Ma X; Shah YM; Guo GL; Wang T; Krausz KW; Idle JR; Gonzalez FJ J Pharmacol Exp Ther; 2007 Jul; 322(1):391-8. PubMed ID: 17442842 [TBL] [Abstract][Full Text] [Related]
4. Tanshinone IIA ameliorates dextran sulfate sodium-induced inflammatory bowel disease via the pregnane X receptor. Zhang X; Wang Y; Ma Z; Liang Q; Tang X; Hu D; Tan H; Xiao C; Gao Y Drug Des Devel Ther; 2015; 9():6343-62. PubMed ID: 26674743 [TBL] [Abstract][Full Text] [Related]
5. Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Cheng J; Shah YM; Gonzalez FJ Trends Pharmacol Sci; 2012 Jun; 33(6):323-30. PubMed ID: 22609277 [TBL] [Abstract][Full Text] [Related]
6. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Sartor RB Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():27-36. PubMed ID: 26618923 [TBL] [Abstract][Full Text] [Related]
7. Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis. Terc J; Hansen A; Alston L; Hirota SA Eur J Pharm Sci; 2014 May; 55():12-9. PubMed ID: 24486481 [TBL] [Abstract][Full Text] [Related]
8. Activation of intestinal human pregnane X receptor protects against azoxymethane/dextran sulfate sodium-induced colon cancer. Cheng J; Fang ZZ; Nagaoka K; Okamoto M; Qu A; Tanaka N; Kimura S; Gonzalez FJ J Pharmacol Exp Ther; 2014 Dec; 351(3):559-67. PubMed ID: 25277138 [TBL] [Abstract][Full Text] [Related]
9. Artemisinin protects against dextran sulfate-sodium-induced inflammatory bowel disease, which is associated with activation of the pregnane X receptor. Hu D; Wang Y; Chen Z; Ma Z; You Q; Zhang X; Zhou T; Xiao Y; Liang Q; Tan H; Xiao C; Tang X; Zhang B; Gao Y Eur J Pharmacol; 2014 Sep; 738():273-84. PubMed ID: 24886881 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Mencarelli A; Renga B; Palladino G; Claudio D; Ricci P; Distrutti E; Barbanti M; Baldelli F; Fiorucci S Eur J Pharmacol; 2011 Oct; 668(1-2):317-24. PubMed ID: 21806984 [TBL] [Abstract][Full Text] [Related]
11. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Shah YM; Ma X; Morimura K; Kim I; Gonzalez FJ Am J Physiol Gastrointest Liver Physiol; 2007 Apr; 292(4):G1114-22. PubMed ID: 17170021 [TBL] [Abstract][Full Text] [Related]
12. The protective effect of piperine on dextran sulfate sodium induced inflammatory bowel disease and its relation with pregnane X receptor activation. Hu D; Wang Y; Chen Z; Ma Z; You Q; Zhang X; Liang Q; Tan H; Xiao C; Tang X; Gao Y J Ethnopharmacol; 2015 Jul; 169():109-23. PubMed ID: 25907981 [TBL] [Abstract][Full Text] [Related]
14. Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Mencarelli A; Migliorati M; Barbanti M; Cipriani S; Palladino G; Distrutti E; Renga B; Fiorucci S Biochem Pharmacol; 2010 Dec; 80(11):1700-7. PubMed ID: 20816942 [TBL] [Abstract][Full Text] [Related]
15. Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation. Zhang J; Ding L; Wang B; Ren G; Sun A; Deng C; Wei X; Mani S; Wang Z; Dou W J Pharmacol Exp Ther; 2015 Feb; 352(2):315-24. PubMed ID: 25472953 [TBL] [Abstract][Full Text] [Related]
16. Pregnane X receptor activation constrains mucosal NF-κB activity in active inflammatory bowel disease. Deuring JJ; Li M; Cao W; Chen S; Wang W; de Haar C; van der Woude CJ; Peppelenbosch M PLoS One; 2019; 14(10):e0221924. PubMed ID: 31581194 [TBL] [Abstract][Full Text] [Related]
17. Plant flavonol isorhamnetin attenuates chemically induced inflammatory bowel disease via a PXR-dependent pathway. Dou W; Zhang J; Li H; Kortagere S; Sun K; Ding L; Ren G; Wang Z; Mani S J Nutr Biochem; 2014 Sep; 25(9):923-33. PubMed ID: 24913217 [TBL] [Abstract][Full Text] [Related]
18. Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway. Esposito G; Gigli S; Seguella L; Nobile N; D'Alessandro A; Pesce M; Capoccia E; Steardo L; Cirillo C; Cuomo R; Sarnelli G Int J Oncol; 2016 Aug; 49(2):639-45. PubMed ID: 27279570 [TBL] [Abstract][Full Text] [Related]